SecBot SecBot
8-K ·Filed Nov 12, 2026

PEPG

PepGen Inc.
BEARISH
Impact 6/10
Horizonimmediate Processed4d 10h ago SEC0001193125-26-458597
8-K material event: Items 1.01
Actionable Insight ▼ Bearish

The $125 million offering more than doubles the company's cash position from $104.8 million to over $220 million, extending its runway into 2028. However, the massive dilution (25 million new shares vs. an estimated 37 million pre-offering shares outstanding) will pressure the stock. Watch for the Q4 2026 earnings report for updated cash runway guidance and clinical trial updates for PGN-EDODM1.

DirectionBearish
Confidencehigh
Horizonimmediate

PGN-EDODM1

▲ Bullish Named in this 8-K
Impact
Phase
Phase 2
Time to market
At least 2-3 years away, assuming positive Phase 2 data in November 2026, an end-of-Phase 2 meeting with regulators in 1H 2027, a subsequent Phase 3 program, and eventual NDA filing.
Next catalyst
None dated

What to watchWatch for the 10 mg/kg data readout from the FREEDOM2-DM1 study expected in November 2026, positive splicing-correction data could drive a significant re-rate given the stock's ~$3.11 price vs. the $10.19 mean analyst target. However, the unresolved FDA partial clinical hold and the active $100M ATM facility are overhangs that could cap upside or accelerate dilution.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$4.36
T+0 close · Nov 12, 2026 · via day close
Latest settled
−3.90%
T+1 · $4.19
Vs SPY
−1.99%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $4.36entry
  2. T+1 · 20h ago −3.90%α −1.99% · $4.19
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PepGen entered into an underwriting agreement for a $125 million public offering of 25 million shares at $5.00 per share, with an option for underwriters to purchase an additional 3.75 million shares. The offering closed simultaneously with this 8-K filing, raising approximately $116.9 million in net proceeds (or $134.5 million if the option is fully exercised). The capital raise represents significant dilution, with the base offering alone adding roughly 73% to the company's pre-offering share count based on the $171 million market cap referenced in the cross-filing context.

Key Financial Metrics

Deal Value
$125.0M

Key Facts

  • PepGen priced a public offering of 25,000,000 shares of common stock at $5.00 per share for gross proceeds of $125 million
  • Underwriters have a 30-day option to purchase up to an additional 3,750,000 shares at the same price
  • Net proceeds estimated at approximately $116.9 million, or $134.5 million if the option is fully exercised
  • The offering was conducted as a takedown from an existing $400 million shelf registration statement (S-3) declared effective May 21, 2026
  • Proceeds will fund ongoing clinical development of PGN-EDODM1, working capital and general corporate purposes
  • The offering closed on the same day as this 8-K filing, with delivery expected on or about November 13, 2026
  • The 424B5 filed on November 10, 2026 noted the company had $104.8 million cash on hand and a Q3 net loss of $19.4 million

Financial Impact

Gross proceeds of $125 million from 25 million shares at $5.00 per share; net proceeds of approximately $116.9 million. The offering size represents roughly 73% of the company's pre-offering market cap of $171 million.

dilutioncash

Risk Factors

  • Massive dilution: the base offering adds approximately 68% to the pre-offering share count, with the option adding another 10%
  • The offering was executed at $5.00 per share, a 13% discount to the prior close of $4.61 on November 10, 2026
  • As a clinical-stage biotech with no approved products, the company remains dependent on capital markets for funding
  • The 60-day lock-up agreements with directors, officers and certain securityholders expire in January 2027, potentially adding selling pressure

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-458597
Document: d80190d8k.htm0001193125-26-458597
Document: d80190dex51.htm0001193125-26-458597
Document: d80190dex991.htm0001193125-26-458597
Document: d80190dex992.htm0001193125-26-458597
Document: 0001193125-26-458597-index-headers.html0001193125-26-458597
Document: 0001193125-26-458597-index.html0001193125-26-458597
Document: 0001193125-26-458597.txt0001193125-26-458597

Track record

12 reports on PEPG

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +31.95% at T+20 after the Aug 6, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Viewing Entry $4.36 to $4.19 Now $4.19 +3.90% ▲ +3.90% +1.99% vs SPY
  2. Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $4.36 to $4.19 Now $4.19 +3.90% ▲ +3.90% +1.99% vs SPY
  3. Nov 10, 20266d ago 424B5 Bearish 6/10 Entry $5.26 to $5.04 Now $4.19 +20.34% ▲ +4.18% +3.83% vs SPY
  4. Nov 10, 20266d ago 8-K Bullish 7/10 Entry $4.61 to $5.26 Now $4.19 −9.11% ▲ +14.10% +12.78% vs SPY
  5. Aug 6, 202614w ago 8-K Bullish 7/10 Entry $2.41 to $2.85 Now $4.19 +73.86% ▲ +18.26% +17.65% vs SPY
  6. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.51 to $1.47 Now $4.19 +177.48% ▼ −2.65% −3.19% vs SPY
  7. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $1.51 to $1.47 Now $4.19 +177.48% ▼ −2.65% −3.19% vs SPY
  8. May 22, 202625w ago EFFECT Bearish 7/10 Entry $1.51 to $1.53 Now $4.19 −177.48% ▼ −1.32% −0.74% vs SPY
  9. May 19, 202625w ago S-3 Bearish 7/10 Entry $1.38 to $1.44 Now $4.19 −203.62% ▼ −4.35% −3.31% vs SPY
  10. May 12, 202626w ago 8-K Neutral 5/10 Entry $1.78 to $1.78 Now $4.19 +135.39% · 0.00% +0.00% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026